By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Novozymes Biopharma 

Castle Court 59 Castle Boulevard

Nottingham    NG7 1FD  United Kingdom
Phone: 44-0115-955-3355 Fax: 44-0115-955-1299



Company News
Novozymes Biopharma Enters License Agreement With EpiVax, Inc. To Advance Pioneering Treatment Of Autoimmune Diseases 12/23/2014 9:15:59 AM
EpiVax, Inc. Enters License Agreement With Novozymes Biopharma To Advance Pioneering Treatment Of Autoimmune Diseases 12/22/2014 9:21:31 AM
Novozymes Biopharma Enters Agreement With A Leading Vaccine Company To Conduct Research On A Novel Subunit Vaccine Complex Based On Albumin Fusion Technology 5/29/2014 10:54:13 AM
Novozymes Biopharma To Offer Drug-Albumin Conjugation Platform In Collaboration With Thiologics 5/13/2014 9:13:07 AM
Novozymes Biopharma Announces Collaboration With Janssen Research & Development To Evaluate Proprietary VELTIS® Half-Life Extension Technology 3/13/2014 9:43:34 AM
Novozymes Biopharma Announces New Data Highlighting Potential For Monthly Drug Dosing 1/27/2014 10:32:10 AM
Novozymes Biopharma Announces Collaboration With Almac Group in Drug Manufacture, Half Life Extension and Targeting Technologies 10/22/2013 8:55:25 AM
Novozymes Biopharma's rAlbumin Approved in Japan as MAQUET Expands Into New Market 2/28/2013 11:36:18 AM
EpiVax, Inc.-Novozymes Biopharma Tregitope-Albumin Fusion Moves "Paradigm-Shifting" Treatment for Diabetes Closer to Clinical Trials 2/12/2013 9:23:05 AM
Novozymes Biopharma Aligns Recombinant Human Albumin Portfolio With New Brand Name 1/29/2013 10:27:43 AM